Enliven Therapeutics Secures $90M for Clinical Research Expansion
Company Announcements

Enliven Therapeutics Secures $90M for Clinical Research Expansion

Enliven Therapeutics (ELVN) has issued an update.

On March 19, 2024, Enliven Therapeutics, Inc. engaged in a significant financing move, entering a securities purchase agreement with select purchasers for a private placement of shares and pre-funded warrants, aiming to raise approximately $90 million. The transaction includes around 5.4 million shares priced at $14 each, and warrants for an additional 1 million shares at a nominal exercise price, with closing expected on March 21, 2024. This strategic financial infusion is earmarked to advance the company’s clinical research and general corporate needs, with sufficient funds projected to support operations well into late 2026.

For an in-depth examination of ELVN stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyEnliven initiated with a Buy at JonesResearch
TheFlyEnliven initiated with a Buy at H.C. Wainwright
TheFlyEnliven price target raised to $39 from $34 at Mizuho
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App